MCID: DRM006
MIFTS: 62

Dermatitis

Categories: Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dermatitis

MalaCards integrated aliases for Dermatitis:

Name: Dermatitis 11 53 5 43 14 71 75
Eczema 11 75 28 53 5 41 63 71
Skin Inflammation 11 14
Inflammatory Dermatosis 71

Classifications:



External Ids:

Disease Ontology 11 DOID:2723
MeSH 43 D003872
NCIt 49 C2983
SNOMED-CT 68 238538009
UMLS 71 C0011603 C0013595 C3875321

Summaries for Dermatitis

MedlinePlus: 41 Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding: Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Dermatitis, also known as eczema, is related to irritant dermatitis and dermatitis herpetiformis, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Salicylic acid and Ciclopirox have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and t cells, and related phenotypes are immune system and hematopoietic system

PubMed Health : 63 Eczema: Eczema is a common, chronic, non-infectious skin condition. The main symptom of this inflammatory disease is a very itchy rash. It often affects children. In many cases eczema gets better as the years go by, and it may go away for a while or disappear altogether. Acute flare-ups can really affect quality of life. The itching can be especially bad, making it difficult to concentrate and sleep well. Some people are embarrassed if their rash is visible to others. By taking good care of your skin, using medication and avoiding irritants and other things that can trigger the eczema, it is usually possible to relieve the symptoms at least enough to live a fairly normal life. Eczema is sometimes also called "atopic eczema" or "atopic dermatitis."

Disease Ontology: 11 A skin disease characterized by itchy, erythematous, vesicular, weeping and crusting patches of skin.

Wikipedia: 75 Dermatitis is inflammation of the skin, typically characterized by itchiness, redness and a rash. In... more...

Related Diseases for Dermatitis

Diseases related to Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2086)
# Related Disease Score Top Affiliating Genes
1 irritant dermatitis 33.2 TSLP IL4 IL31 IL13 FLG CCL27
2 dermatitis herpetiformis 33.2 IL5 IL4 IL31 CCL11
3 allergic contact dermatitis 33.2 TSLP SPINK5 IL5 IL4 IL31RA IL31
4 contact dermatitis 33.2 TSLP SPINK5 IL5 IL4 IL31RA IL31
5 dermatitis, atopic 33.2 TSLP SPINK5 NOD2 IL5 IL4 IL31RA
6 seborrheic infantile dermatitis 33.0 ZNF750 FLG
7 cercarial dermatitis 33.0 IL5 IL4
8 eczema herpeticum 32.9 TSLP SPINK5 IL4 IL31 IL13 IGHE
9 occupational dermatitis 32.8 IL31 FLG
10 seborrheic dermatitis 32.7 ZNF750 SPINK5 FLG DSG1 BTD
11 nickel allergic contact dermatitis 32.7 IL5 IL13
12 chromium allergic contact dermatitis 32.6 IL5 IL4 IL13
13 blau syndrome 32.6 NOD2 NLRP3 IL4
14 allergic rhinitis 32.4 IL5 IL4 IL13 IGHE CCL17 CCL11
15 bullous pemphigoid 32.3 IL5 IL4 IGHE DSG1 CCL17 CCL11
16 celiac disease 1 32.3 TSLP NOD2 IL5 IL4 IL13
17 netherton syndrome 32.3 SPINK5 IGHE FLG DSG1
18 allergic asthma 32.2 TSLP IL5 IL4 IL13 IGHE CCL17
19 ige responsiveness, atopic 32.2 SPINK5 IL5 IL4 IL13 IGHE
20 chronic rhinitis 32.1 IL5 IL4 IL13
21 metal allergy 32.1 IL5 IL4 IL13 FLG
22 milk allergy 32.1 TSLP IL5 IL4 IL13 IGHE
23 egg allergy 32.0 TSLP IL5 IL4 IL13 IGHE FLG
24 hyper ige syndrome 32.0 SPINK5 IL4 IGHE CCL11
25 rhinitis 32.0 TSLP IL5 IL4 IL13 IGHE FLG
26 food allergy 32.0 TSLP IL5 IL4 IL13 IGHE FLG
27 neurodermatitis 32.0 TSLP IL4 IL31RA IL31 IL13 FLG
28 pollen allergy 32.0 IL5 IL4 IL13
29 skin disease 32.0 TSLP SPINK5 NOD2 NLRP3 IL5 IL4
30 allergic disease 32.0 TSLP IL5 IL4 IL13 IGHE FLG
31 filariasis 31.9 IL5 IL4 IL13 IGHE
32 onchocerciasis 31.9 IL5 IL4 IL13 IGHE DSG1 CCL11
33 psoriasis 31.9 SPINK5 NOD2 IL5 IL4 IL31 IL13
34 pyoderma 31.9 NOD2 NLRP3 DSG1
35 asthma 31.8 TSLP SPINK5 NOD2 NLRP3 IL5 IL4
36 urticaria 31.7 TSLP NLRP3 IL5 IL4 IL31 IL13
37 hypereosinophilic syndrome 31.7 IL5 IL4 IL13 IGHE CCL17 CCL11
38 conjunctivitis 31.7 NLRP3 IL5 IL4 IL13 IGHE CCL11
39 erythema multiforme 31.6 IL5 IL4 IL13 CCL17
40 pemphigoid 31.5 IL5 IL4 IL31 IL13 DSG1 CCL11
41 fungal infectious disease 31.5 IL5 IL4 IL13
42 folliculitis 31.5 IL5 IL4 CCL11
43 skin atrophy 31.4 IL4 IL31 FLG
44 mycosis fungoides 31.4 IL5 IL4 CCL22 CCL17
45 lichen planus 31.4 IL4 FLG DSG1
46 ichthyosis vulgaris 31.4 TSLP SPINK5 FLG DSG1
47 alopecia areata 31.4 IL4 IL13 FLG
48 scabies 31.3 IL5 IL4 IL31 IL13 FLG
49 schistosomiasis 31.3 IL5 IL4 IL13 IGHE
50 primary cutaneous t-cell non-hodgkin lymphoma 31.3 IL5 IL4 CCL17

Graphical network of the top 20 diseases related to Dermatitis:



Diseases related to Dermatitis

Symptoms & Phenotypes for Dermatitis

UMLS symptoms related to Dermatitis:


pruritus; exanthema

MGI Mouse Phenotypes related to Dermatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.77 CCL11 CCL17 CCL22 CMA1 IGHE IL13
2 hematopoietic system MP:0005397 9.44 CCL11 CCL17 CMA1 DSG1 IGHE IL13

Drugs & Therapeutics for Dermatitis

PubMed Health treatment related to Dermatitis: 63

Eczema is a chronic condition. Treatment cannot cure it, but regular skin care and medication can help to keep the itching and rash at bay. The main treatment options are: Basic treatment : Lipid -replenishing and moisturizing products (emollients ) are generously applied to the skin at least twice a day to keep it from drying out. This can help relieve itching and protect the skin from germs and irritants. Special soaps, liquid cleansers and shampoos : Normal soaps and products like shampoo or shower gel contain various substances that can dry out your skin . Special cleansing products without these substances are available to get around this problem. But basic treatment with emollients can usually compensate for the loss of moisture caused by normal soaps. Steroid creams : Eczema flare -ups are usually treated with steroid creams because they can relieve the itching and inflammation . They are typically used only for acute symptoms. But they are sometimes used at regular intervals together with moisturizing skin care products (basic treatment ): for example, as a "weekend treatment" where a steroid cream is applied on one or two days a week. Pimecrolimus and tacrolimus : Pimecrolimus and tacrolimus are two other medicines that can be used to treat eczema . They are not approved for use in children under the age of two years, though. These two medicines are also applied to the skin in a cream or ointment, and can be used if steroid products are not an option. This might be the case if steroid treatment is not tolerated or is ineffective. Pimecrolimus and tacrolimus may also be an option for long-term treatment of sensitive skin in the face and neck area. They can also be used on one or two days per week only, as described above. Other eczema treatment options include wet wraps, UV radiation and medications that suppress certain immune responses. Tablets containing these medicines are used if other treatments don't work, or if the eczema is very severe or affects large areas of skin . Because they have an effect throughout the entire body, they may have more extensive side effects than topical treatments. Allergy medications (antihistamines ) are also commonly used to relieve itching . But research has now shown that they are not suitable for treating eczema , whether used as tablets or a cream. People often try out herbal products or dietary supplements, such as evening primrose oil , borage oil, vitamin B6, vitamin E and zinc . But research hasn't shown that these products are effective. Many other treatments such as laser therapies or hyposensitization have not yet been studied enough, so they are not recommended by medical associations.

Drugs for Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 471)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
2
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
3
Titanium dioxide Approved Phase 4 13463-67-7
4
Glycerin Approved, Investigational Phase 4 56-81-5 753
5
Carbamide peroxide Approved Phase 4 124-43-6
6
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
7
Omalizumab Approved, Investigational Phase 4 242138-07-4
8
Levocetirizine Approved Phase 4 130018-77-8 1549000
9
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
10
Desonide Approved, Investigational Phase 4 638-94-8 5311066
11
Montelukast Approved Phase 4 158966-92-8 5281040
12
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8 4474933
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
15
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
16
Desoximetasone Approved Phase 4 382-67-2 5311067
17
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
18
Brodalumab Approved, Investigational Phase 4 1174395-19-7
19
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
20
Dicloxacillin Approved, Investigational, Vet_approved Phase 4 3116-76-5 18381
21
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
22
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
23
Apremilast Approved, Investigational Phase 4 608141-41-9 10151715 11561674
24
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
25
Alitretinoin Approved, Investigational Phase 4 5300-03-8 449171
26
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6509979
27
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
28
Zinc oxide Approved Phase 4 1314-13-2
29
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
30
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
31
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
32
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
33
Lactitol Approved, Investigational Phase 4 585-86-4 157355
34
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
35
Dapsone Approved, Investigational Phase 4 80-08-0 2955
36
Cefuroxime Approved Phase 4 55268-75-2 5479529
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Halometasone Experimental Phase 4 50629-82-8 12811517
39
Cortisone Experimental Phase 4 53-06-5 222786
40 Cyclooxygenase Inhibitors Phase 4
41
Salicylates Phase 4
42 Acidophilus Phase 4
43 Immunoglobulin E Phase 4
44 Histamine H1 Antagonists, Non-Sedating Phase 4
45 Olive Phase 4
46 Leukotriene Antagonists Phase 4
47 Anti-Arrhythmia Agents Phase 4
48 Sodium Channel Blockers Phase 4
49 Diuretics, Potassium Sparing Phase 4
50 Epinephryl borate Phase 4

Interventional clinical trials:

(show top 50) (show all 1557)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
2 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
3 Effects of Interleukin (IL)-4/IL-13 Blockade on the Structure and Function of Cutaneous Sensory Nerves: An Open-label, Single-arm Longitudinal Study With Dupilumab Unknown status NCT04520308 Phase 4 Dupilumab Only Product
4 A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study Unknown status NCT03257215 Phase 4 Stoss vitamin D;Daily vitamin D;Stoss placebo;Daily placebo
5 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
6 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
7 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
8 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
9 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
10 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
11 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A
12 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
13 A Multicenter, Open Uncontrolled Clinical Study to Examine the Efficacy and Safety of Zarzenda in the Management of Hand Eczema Completed NCT00488241 Phase 4
14 Quality of Life Study in Adults With Facial Eczema Completed NCT00120302 Phase 4 Pimecrolimus;Placebo
15 A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema Completed NCT00576550 Phase 4 Urea;betamethasone valerate
16 The Clinical Study of the Microbial Colonization of Chronic Keratinized Hand Eczema and the Change of Microbial Colonization After External Using of Halometasone Triclosan Cream Completed NCT03246776 Phase 4 Halometasone Triclosan
17 An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
18 A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
19 Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Completed NCT02732314 Phase 4 Investigational OTC Cream;0.05% Desonide Cream
20 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
21 The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Completed NCT04114097 Phase 4 Betnovate, betamethasone dipropionate ointment 0.1% and placebo;Protopic, tacrolimus ointment 0.1%
22 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Completed NCT01126268 Phase 4 Retapamulin (Altabax)
23 PDE4A Expression as a Biomarker of Responsiveness to Eucrisa Completed NCT04023084 Phase 4 Crisaborole
24 Randomized Single-blind Study on the Adherence to Treatment With Topical Methylprednisolone Aceponate (Advantan®) in Different Vehicles (AD-HERE) Completed NCT04016025 Phase 4
25 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
26 Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
27 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
28 Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis Completed NCT00819507 Phase 4 Fluocinonide
29 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
30 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
31 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
32 Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study Completed NCT02589392 Phase 4
33 A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis Completed NCT00510003 Phase 4 Pimecrolimus
34 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
35 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
36 Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis Completed NCT03050294 Phase 4 Desoximetasone 0.25% spray
37 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
38 A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment Completed NCT00673725 Phase 4 Locobase® REPAIR
39 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
40 A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS Completed NCT03356977 Phase 4 Crisaborole ointment 2%
41 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
42 A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
43 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
44 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
45 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
46 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
47 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo
48 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
49 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
50 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo

Search NIH Clinical Center for Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alclometasone
alclometasone dipropionate
amcinonide
Clobetasol
Clobetasol Propionate
cocoa butter
Cod Liver Oil
Colloidal oatmeal
eucerin
EUCERITE
Glycerin
GLYCERIN LIQUID
GLYCERIN,ANHYDROUS
GLYCERIN,DEHYDRATED
Lactic acid
LACTIC ACID LIQUID
LACTIC ACID,BUFFERED
methdilazine
Methdilazine hydrochloride
OATMEAL 1 g in 1 g TOPICAL POWDER [Soothing Bath Treatment]
Racemethionine
retinol acetate
retinyl palmitate
Vitamin A
VITAMIN A (AS ACETATE & BETA CAROTENE)
VITAMIN A (AS PALMITATE & BETA CAROTENE)
VITAMIN A (NATURAL)
VITAMIN A PALMITATE (SOLUBILIZED)
Zinc Oxide

Cochrane evidence based reviews: dermatitis

Genetic Tests for Dermatitis

Genetic tests related to Dermatitis:

# Genetic test Affiliating Genes
1 Eczema 28

Anatomical Context for Dermatitis

Organs/tissues related to Dermatitis:

MalaCards : Skin, Breast, T Cells, Neutrophil, Liver, Pituitary, Bone

Publications for Dermatitis

Articles related to Dermatitis:

(show top 50) (show all 48557)
# Title Authors PMID Year
1
Prevalence and risk factors of work-related contact dermatitis symptoms among healthcare cleaners during the COVID-19 pandemic in Northwest Ethiopia: a multicentre cross-sectional survey. 62 41
36446456 2022
2
Influence of the environment on the characteristics of asthma. 62 41
36443644 2022
3
Ultra-processed foods and allergic symptoms among children and adults in the United States: A population-based analysis of NHANES 2005-2006. 62 41
36407984 2022
4
Elder siblings enhance the effect of filaggrin mutations on childhood eczema: results from the 2 birth cohort studies LISAplus and GINIplus. 53 62
20513523 2010
5
IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. 53 62
20357258 2010
6
Increased risk of eczema but reduced risk of early wheezy disorder from exclusive breast-feeding in high-risk infants. 53 62
20236698 2010
7
Interleukin-4 receptor polymorphisms in asthma and allergy: relation to different disease phenotypes. 53 62
20002627 2010
8
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. 53 62
20112373 2010
9
Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. 53 62
20199415 2010
10
Hyper-IgE syndrome with STAT3 mutation: a case report in Mainland China. 53 62
20490271 2010
11
Chromosome 11q13.5 variant associated with childhood eczema: an effect supplementary to filaggrin mutations. 53 62
20109745 2010
12
Human leukocyte antigen (DR1)-DQB1*0501 and (DR15)-DQB1*0602 haplotypes are associated with humoral responses to early food allergens in children. 53 62
20016199 2010
13
A multi-centre study of candidate genes for wheeze and allergy: the International Study of Asthma and Allergies in Childhood Phase 2. 53 62
20085599 2009
14
Melatonin inhibits the development of 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. 53 62
19817972 2009
15
Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. 53 62
19681860 2009
16
Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease. 53 62
19408338 2009
17
Contribution of itch-associated scratch behavior to the development of skin lesions in Dermatophagoides farinae-induced dermatitis model in NC/Nga mice. 53 62
18979107 2009
18
Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. 53 62
19538184 2009
19
IL-18 and skin inflammation. 53 62
19285156 2009
20
Polyclonal IgE induces mast cell survival and cytokine production. 53 62
19542764 2009
21
Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. 53 62
19665780 2009
22
Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. 53 62
19706451 2009
23
Filaggrin in atopic dermatitis. 53 62
19720209 2009
24
Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. 53 62
19541355 2009
25
Atopic dermatitis in adults: evaluation of peripheral blood mononuclear cells proliferation response to Staphylococcus aureus enterotoxins A and B and analysis of interleukin-18 secretion. 53 62
19469892 2009
26
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. 53 62
19351959 2009
27
Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. 53 62
19501237 2009
28
Risk analysis of early childhood eczema. 53 62
19501236 2009
29
The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes. 53 62
19371952 2009
30
A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. 53 62
19349982 2009
31
An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. 53 62
19348926 2009
32
Clinical severity correlates with impaired barrier in filaggrin-related eczema. 53 62
18818676 2009
33
Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. 53 62
19088064 2009
34
[Relationship between gene polymorphism of CYP2E1, CYP1A1, IL-4 and medicamentosa-like dermatitis induced by trichloroethylene]. 53 62
19351467 2009
35
Early-life rotavirus and norovirus infections in relation to development of atopic manifestation in infants. 53 62
19032360 2009
36
Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. 53 62
19147084 2009
37
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 53 62
19471859 2009
38
Elevated serum immunoglobulin E (IgE): when to suspect hyper-IgE syndrome-A 10-year pediatric tertiary care center experience. 53 62
19331717 2009
39
Hyper IgE (Job's) syndrome: a primary immune deficiency with oral manifestations. 53 62
19036057 2009
40
Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. 53 62
18795918 2009
41
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. 53 62
18951619 2008
42
Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. 53 62
18978467 2008
43
Early atopic disease and early childhood immunization--is there a link? 53 62
18925883 2008
44
Classification of atopic hand eczema and the filaggrin mutations. 53 62
18976374 2008
45
Nickel sensitization, hand eczema, and loss-of-function mutations in the filaggrin gene. 53 62
19134432 2008
46
Enhanced CCL26 production by IL-4 through IFN-gamma-induced upregulation of type 1 IL-4 receptor in keratinocytes. 53 62
18774776 2008
47
Cytokine response after severe respiratory syncytial virus bronchiolitis in early life. 53 62
18760461 2008
48
Expired nitric oxide and airway reactivity in infants at risk for asthma. 53 62
18760452 2008
49
Novel immunological approaches in the treatment of atopic eczema. 53 62
18769195 2008
50
Filaggrin in atopic dermatitis. 53 62
18774165 2008

Variations for Dermatitis

ClinVar genetic disease variations for Dermatitis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FLG NM_002016.2(FLG):c.2282_2285del (p.Ser761fs) MICROSAT Pathogenic
16320 rs558269137 GRCh37: 1:152285077-152285080
GRCh38: 1:152312601-152312604
2 FLG NM_002016.2(FLG):c.1501C>T (p.Arg501Ter) SNV Pathogenic
16319 rs61816761 GRCh37: 1:152285861-152285861
GRCh38: 1:152313385-152313385
3 NLRP3 NM_001243133.2(NLRP3):c.1700A>G (p.Glu567Gly) SNV Likely Pathogenic
1700698 GRCh37: 1:247588451-247588451
GRCh38: 1:247425149-247425149
4 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu) SNV Uncertain Significance
598996 rs1558697792 GRCh37: 2:31602803-31602803
GRCh38: 2:31379937-31379937
5 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His) SNV Uncertain Significance
335760 rs143981573 GRCh37: 2:31562482-31562482
GRCh38: 2:31339616-31339616
6 ITGA3 NM_002204.4(ITGA3):c.1766G>C (p.Arg589Pro) SNV Uncertain Significance
1339481 GRCh37: 17:48153781-48153781
GRCh38: 17:50076417-50076417

Expression for Dermatitis

Search GEO for disease gene expression data for Dermatitis.

Pathways for Dermatitis

Pathways related to Dermatitis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CCL11 CCL22 DSG1 FAF2 IL13 IL31
2
Show member pathways
13.52 CCL11 CCL17 CCL22 CCL27 IL13 IL31
3
Show member pathways
13.28 IL5 IL4 IL13 CCL27 CCL22 CCL17
4
Show member pathways
13.18 IL5 IL4 IL13 CCL27 CCL22 CCL17
5
Show member pathways
12.99 TSLP NOD2 IL5 IL4 IL31RA IL31
6
Show member pathways
11.95 CCL27 CCL22 CCL17 CCL11
7 11.84 IL4 IL13 CCL22 CCL11
8 11.74 IL5 IL4 IL13
9 11.66 TSLP IL5 IL4 IL13
10 11.65 IL5 IL4 IL13
11
Show member pathways
11.6 IL31RA IL31 CCL11
12 11.51 IL5 IL4 CCL17 CCL11
13
Show member pathways
11.44 NOD2 IL5 IL4 IL13
14 11.17 IL5 IL4 IL13
15 11.15 IL5 IL4 IL13 CMA1 CCL11
16 11.13 IL5 IL4 IL13
17 11.09 IL5 IL4 IL13
18 10.96 TSLP IL5 IL4 IL13
19 10.83 IL5 IL4 IL31 IL13 CCL22 CCL17
20 10.77 CCL11 CCL17 CCL22 CCL27 IL13 IL4
21 10.66 IL5 IL4 IL13

GO Terms for Dermatitis

Cellular components related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.03 TSLP IL5 IL4 IL31 IL13 IGHE
2 extracellular region GO:0005576 9.78 BTD CCL11 CCL17 CCL22 CCL27 CMA1

Biological processes related to Dermatitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.21 CCL11 CCL17 CCL22 IL13 IL5 NLRP3
2 chemotaxis GO:0006935 10.11 CCL27 CCL22 CCL17 CCL11
3 monocyte chemotaxis GO:0002548 9.97 CCL11 CCL17 CCL22
4 positive regulation of B cell proliferation GO:0030890 9.95 IL13 IL4 IL5
5 lymphocyte chemotaxis GO:0048247 9.88 CCL22 CCL17 CCL11
6 negative regulation of macrophage activation GO:0043031 9.86 IL4 IL31RA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 TSLP IL4 IL31RA IL13
8 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.85 NLRP3 IL4
9 positive regulation of type 2 immune response GO:0002830 9.76 NOD2 NLRP3
10 negative regulation of acute inflammatory response GO:0002674 9.71 NLRP3 IL4
11 cellular response to peptidoglycan GO:0071224 9.7 NOD2 NLRP3
12 negative regulation of complement-dependent cytotoxicity GO:1903660 9.67 IL4 IL13
13 positive regulation of interleukin-10 production GO:0032733 9.56 TSLP NOD2 IL4 IL13
14 positive regulation of interleukin-13 production GO:0032736 9.55 IL4 NLRP3 TSLP
15 detection of biotic stimulus GO:0009595 9.5 NOD2 NLRP3
16 immune response GO:0006955 9.47 IL5 IL4 IL13 IGHE CCL27 CCL22

Molecular functions related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.73 CCL22 CCL17 CCL11
2 CCR3 chemokine receptor binding GO:0031728 9.62 CCL27 CCL11
3 chemokine activity GO:0008009 9.56 CCL27 CCL22 CCL17 CCL11
4 cytokine activity GO:0005125 9.47 TSLP IL5 IL4 IL31 IL13 CCL27
5 cytokine receptor binding GO:0005126 9.46 IL4 IL31 IL13

Sources for Dermatitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....